ImmunityBio Inc

ImmunityBio, Inc. ( formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient's natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells.

Our vaccine technologies are developed to deliver tumor-associated antigens (TAAs) and neoepitopes (expressed only by cancer cells), including hAd5, our second-generation adenovirus. These are intended to induce T-cell memory through the activation of CD4+ and CD8+ T cells, along with antibody (humoral) responses. Our hAd5 technology has produced several product candidates that have been studied in Phase I and II clinical trials as potential vaccines for certain cancers; these candidates have shown an ability to overcome previous adenovirus immunity in cancer patients and preclinical models. The hAd5 technology has also been used with common TAAs to establish memory T cells in multiple clinical trials.